Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report

RATIONALE: With the recent advancements in molecular biology research, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have emerged as excellent therapies for patients with EGFR-mutant cancers. However, these patients inevitably develop cross-acquired resistance to EGFR-TKIs....

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yiqian, Shou, Leyi, Guo, Qingmin, Bao, Yanhong, Xu, Xiaoping, An, Suhong, Lu, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360407/
https://www.ncbi.nlm.nih.gov/pubmed/34397927
http://dx.doi.org/10.1097/MD.0000000000026911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360407/
https://www.ncbi.nlm.nih.gov/pubmed/34397927
http://dx.doi.org/10.1097/MD.0000000000026911

Ejemplares similares